Key Highlights

  • Third-quarter sales for Ainos (NASDAQ:AIMD) landed at USD 642,889, compared with a mere USD 2,167 twelve months prior, and USD 600,000 of that came from licensing VELDONA interferon intellectual property.
  • The net loss shrank by 36% to USD 1,886,074 from USD 2,931,702, while Research and Development outlays dropped 15% to USD 1,696,019.
  • Cash stood at USD 660,916 on September 30, 2026, versus USD 16,594,900 of current liabilities, which include USD 11,000,000 of convertible notes falling due within a year.
  • The filing flags substantial doubt about the company remaining a Going Concern and reports an accumulated Deficit of USD 76,460,933.

A One-Off Licence Fee Explains the Jump to USD 642,889

Ainos (NASDAQ:AIMD) filed its results for the quarter ended September 30, 2026 on November 16, 2026. Quarterly Revenue totalled USD 642,889, whereas the third quarter of 2025 produced only USD 2,167. Of the current figure, USD 600,000 reflects a licence tied to VELDONA, the firm's low-dose oral interferon effort, and USD 42,750 reflects AI Nose hardware placed in semiconductor production. Gross Profit reached USD 536,266, up from USD 1,690. The Texas-incorporated company works on AI-based scent detection marketed as Smell ID, alongside immune therapies. Management outlined a licensing structure with potential worth of USD 10 million, starting with Sjogren disease and thrombocytopenia and leaving room for 15 further indications in later deals. It also said deliveries of 1,400 AI Nose units under an initial three-year USD 2.1 million arrangement have been completed.

Lower Spending Brings the Quarterly Loss to USD 1,886,074

Total operating outlays declined 20% to USD 2,220,938, against USD 2,785,883 before. Research and development spending came in at USD 1,696,019 versus USD 1,990,630, and selling, general and administrative expense was USD 524,919 compared with USD 795,253. Operating losses narrowed to USD 1,684,672 from USD 2,784,193, yet interest charges increased to USD 204,763. Ultimately the net loss stood at USD 1,886,074, against USD 2,931,702. Across nine months, sales were USD 643,202 versus USD 113,037, and the net loss totalled USD 8,940,605 against USD 10,302,714. Excluding share-based compensation and depreciation, the adjusted quarterly loss was USD 672,352. Cash used in operations over nine months came to USD 3,429,677.

Thin Liquidity, Convertible Notes and the Going-Concern Question

Ainos (NASDAQ:AIMD) holds a Balance Sheet that worries lenders: cash of USD 660,916 sits against total Assets of USD 18,315,937, and every USD 16,594,900 of liabilities is current. The USD 11,000,000 of convertible notes was reclassified from non-current, and a USD 2,812,940 Loan payable arrived during the nine months. Equity dropped to USD 1,721,037 from USD 7,562,582, with intangibles accounting for USD 15,843,468 of assets. The company collected USD 950,000 of receivables after quarter-end, which management views as helpful for liquidity. Earlier this year it sold 436,857 shares through its at-the-market facility, netting USD 830,435. Shares outstanding total 7,554,324, so new equity would dilute existing holders.

Where Things Stand

The jump reflected a single licence payment, not a broad sales base. Ainos (NASDAQ:AIMD) moved revenue from USD 2,167 to USD 642,889 mostly through USD 600,000 of VELDONA licensing and narrowed its net loss to USD 1,886,074. Even so, the filing flags doubt over the company's footing as a going concern, while USD 660,916 of cash must cover USD 11,000,000 of convertible notes now classed as current. Next, watch for more AI Nose orders from semiconductor plants, further VELDONA licences and the timing of the next financing.